Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

• Former head of psychiatry products at FDA joins Cybin team.
• Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz).

A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory pathway as it studies and develops psychedelic medicines, says Alex Belser, Cybin’s chief clinical officer.

“Psychedelic medicines don’t fit neatly into the old models for how drugs are studied, reviewed and approved,” says Belser. “We brought together experts to help us work within existing clinical and regulatory frameworks while realizing that psychedelics require innovative methods and a new approach.”

During his tenure at the FDA, Laughren supervised the research and review of all new psychiatric drug applications and development projects in clinical testing. In addition, he assisted in the design and interpretation of clinical trials for psychiatric drugs. Laughren left the FDA in 2021 to start his own consulting company and has spent the last decade helping psychiatric pharmaceutical drug makers gain FDA approval for new drugs.

Cybin CEO Doug Drysdale notes that Laughren’s FDA experience is invaluable as the company moves into the “next chapter” with studies on psilocybin, the psychedelic compound found in “magic” mushrooms. “Building and maintaining strong relationships and communications channels with regulators will be important for Cybin as their understanding of psychedelic therapeutics evolves over time,” says Drysdale. 

Although Cybin is currently conducting studies on psilocybin, the company is also developing novel molecules based on other psychedelic compounds. In fact, the company has 13 provisional patent applications filed for novel psychedelic molecules.

Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.